CureVac Acquisition Enters Final Phase as BioNTech Integration Accelerates

CureVac NL0015436031

The new trading year has begun on a positive note for CureVac, with its shares posting significant gains. This upward movement reflects the market’s anticipation of the final stages of its acquisition by fellow German biotech firm BioNTech. Investor focus has now shifted to the technical completion of the deal and the timeline for CureVac’s eventual disappearance as an independent listed entity.

• Share Movement: Shares advanced approximately 4.5% to €3.78.
• Majority Stake: BioNTech already controls a commanding 81.74% of CureVac’s equity.
• Formal Completion: The transaction is expected to be formally finalized in January 2026.
• Management Shift: A key executive departure signals deepening integration efforts.